Determining Clinically Meaningful Improvement in Children and Adolescents with Tourette Syndrome Receiving Pharmacotherapy
Journal of Child and Adolescent Psychopharmacology · 2025
DOI: 10.1089/cap.2025.0036 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Child and Adolescent Psychopharmacology, 2025. Verfasst von Joseph F McGuire und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Tourette Syndrome, Minimal Clinically Important Difference. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction
Accurate assessment of treatment outcomes in patients with Tourette syndrome (TS) is essential for evidence-based clinical care. This report determined the minimal clinically important difference (MCID) on the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (YGTSS-TTS) and YGTSS Impairment Scale (YGTSS-I), using the Clinical Global Impression of TS Severity (CGI-TS-S) and Improvement (CGI-TS-I) as anchors, in pediatric patients with TS receiving pharmacotherapy. Materials and Methods: Analyses used data from two clinical trials of ecopipam (a randomized controlled trial and its open-label extension). Receiver operating characteristic (ROC) analysis determined the percentage reduction in YGTSS scores that distinguished patients with improvement from those with no change or worsening on the CGI-TS-S and CGI-TS-I. Spearman’s correlation, empirical cumulative distribution function, and probability distribution function analyses examined relationships between YGTSS-TTS and CGI-TS-S or CGI-TS-I.
Results
Overall, 133 patients (75.2% male; mean [SD] age, 12.7 [2.8]) were included; 63.2% had improvement on the CGI-TS-S, and 78.2% showed improvement on the CGI-TS-I. Percentage reduction in YGTSS scores that distinguished improvement from no change or worsening on the CGI-TS-S and CGI-TS-I ranged from 18.6%–33.3% (area under the ROC curve range, 0.71–0.81). Improvement on the YGTSS-TTS was correlated with posttreatment CGI-TS-S ( r = −0.65; p < 0.001) and CGI-TS-I ( r = −0.61; p < 0.001) scores. The MCID for YGTSS-TTS was achieved by 67% and 62% of patients with improvement on the CGI-TS-S and CGI-TS-I, respectively.
Conclusions
This analysis is the first to determine the MCID for YGTSS in a pediatric population with TS receiving pharmacotherapy. Whether using CGI-TS-S or CGI-TS-I as the anchor, a 25% reduction in YGTSS scores was a generally appropriate minimum threshold to define clinically meaningful improvement in this population. Findings offer an objective threshold for classifying clinically meaningful improvement in children and adolescents receiving pharmacotherapy for TS in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Emalex Biosciences, Inc., Chicago, Illinois, USA.
- Bittman Biostat, Inc., Naples, Florida, USA.
- Paragon Biosciences, LLC, Chicago, Illinois, USA.
- Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
ORCID-Profile: Joseph F McGuire
Zitieren
APA
McGuire, J. F., Karkanias, G. B., Bittman, R. M., Atkinson, S. D., Munschauer, F. E., Wanaski, S. P., Cunniff, T. M., & Gilbert, D. L. (2025). Determining Clinically Meaningful Improvement in Children and Adolescents with Tourette Syndrome Receiving Pharmacotherapy. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2025.0036
Vancouver
McGuire JF, Karkanias GB, Bittman RM, Atkinson SD, Munschauer FE, Wanaski SP, et al. Determining Clinically Meaningful Improvement in Children and Adolescents with Tourette Syndrome Receiving Pharmacotherapy. Journal of Child and Adolescent Psychopharmacology. 2025. doi:10.1089/cap.2025.0036
BibTeX
@article{McGuire2025,
author = {McGuire, Joseph F and Karkanias, George B and Bittman, Richard M and Atkinson, Sarah D and Munschauer, Frederick E and Wanaski, Stephen P and Cunniff, Timothy M and Gilbert, Donald L},
title = {Determining Clinically Meaningful Improvement in Children and Adolescents with Tourette Syndrome Receiving Pharmacotherapy},
journal = {Journal of Child and Adolescent Psychopharmacology},
year = {2025},
doi = {10.1089/cap.2025.0036}
}
EUVIMED